A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-06-06
Target enrollment:
Participant gender:
Summary
This is a dose-escalation and expansion, open label, single centre, phase Ib study. In this
study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride
liposome injection in combination with 5-FU/LV were studied in patients with advanced solid
tumors. Meanwhile, to determine the dose-limiting toxicity (DLT) and maximum tolerated dose
(MTD) of irinotecan hydrochloride liposome.